Treatment of pseudoptosis secondary to aberrant regeneration of the facial nerve with botulinum toxin type A

Ophthalmic Plastic and Reconstructive Surgery

Volumn 29, Issue 3, 2013, Pages 175-178

  McElhinny, Elaine R ^a   Reich, Isaac ^a   Burt, Benjamin ^b   Mancini, Ronald ^c   Wladis, Edward J ^d   Durairaj, Vikram D ^e   Shinder, Roman ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d ALBANY MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; ARTICLE; BELL PALSY; CLINICAL ARTICLE; DISEASE DURATION; EYELID DISEASE; FACIAL NERVE; FACIAL NERVE PARALYSIS; FEMALE; FOLLOW UP; HERPES ZOSTER OTICUS; HUMAN; INJECTION; INJURY; LOW DRUG DOSE; MALE; NERVE REGENERATION; ORBICULARIS OCULI MUSCLE; PRIORITY JOURNAL; PSEUDOPTOSIS; RETROSPECTIVE STUDY; SURGICAL INJURY; UPPER EYELID;

ADULT; AGED; BLEPHAROPTOSIS; BOTULINUM TOXINS, TYPE A; FACIAL MUSCLES; FACIAL NERVE; FACIAL PARALYSIS; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NERVE REGENERATION; NEUROMUSCULAR AGENTS; RETROSPECTIVE STUDIES; SYNKINESIS;

EID: 84880060085     PISSN: 07409303     EISSN: 15372677     Source Type: Journal    
DOI: 10.1097/IOP.0b013e3182873d7d     Document Type: Article

References (27)

1. Cohen AJ, Weinberg dA Pseudoptosis. In: Cohen AJ, Weinberg dA, eds. Evaluation and Management of Blepharoptosis. New York: Springer, 2011:61-5.
2. Montserrat L, Benito M. Facial synkinesis and aberrant regeneration of facial nerve. In: Jankovic J, Tolosa E, eds. Advances in Neurology: Facial Dyskinesias. Vol. 49. New York: Raven Press, 1988:211-24.
3. Yamamoto E, Nishimura H, Hirono Y. Occurrence of sequelae in Bell's palsy. Acta Otolaryngol Suppl 1988;446:93-6.
4. Peitersen E. The spontaneous course of 2,500 peripheral facial nerve palsies of different etiologies. Acta Otolaryngol Suppl 2002;549:4-30.
5. Taverner d. Bell's palsy: a clinical and electromyographic study. Brain 1955;78:209-28.
6. Maeyama H, Aoyagi M, Tojima H., et al Electrophysiological study on the pathology of synkinesis after facial nerve paralysis. Acta Otolaryngol Suppl 1994;511:161-4.
7. Yamada H, Hato N, Murakami S., et al Facial synkinesis after experimental compression of the facial nerve comparing intratemporal and extratemporal lesions. Laryngoscope 2010;120:1022-7.
8. Celik M, Forta H, Vural C. The development of synkinesis after facial nerve paralysis. Eur Neurol 2000;43:147-51.
9. Kanaya K, Ushio M, Kondo K., et al Recovery of facial movement and facial synkinesis in Bell's palsy patients. Otol Neurotol 2009;30:640-4.
10. Adour KK, Wingerd J, Bell d.N., et al Prednisone treatment for idiopathic facial paralysis (Bell's palsy). N Engl J Med 1972;287:1268-72.
11. Austin JR, Peskind S P, Austin SG, et al Idiopathic facial nerve paralysis: a randomized double blind controlled study of placebo versus prednisone. Laryngoscope 1993;103:1326-33.
12. Azuma T, Nakamura K, Takahashi M., et al Mirror biofeedback rehabilitation after administration of single-dose botulinum toxin for treatment of facial synkinesis. Otolaryngol Head Neck Surg 2012;146:40-5.
13. Wiener A, Touloei K, Glick B P. A novel long-term therapy of facial synkinesis with botulinum neurotoxins type A and fillers. J Clin Aesthet Dermatol 2011;4:45-9.
14. Guerrissi JO. Selective myectomy for postparetic facial synkinesis. Plast Reconstr Surg 1991;87:459-66.
15. Lai CS, Lu SR, Yang S F, et al Surgical treatment of the synki-netic eyelid closure in Marin-Amat syndrome. Ann Plast Surg 2011;67:498-501.
16. Borodic GE, Pearce LB, Cheney M, et al Botulinum A toxin for treatment of aberrant facial nerve regeneration. Plast Reconstr Surg 1993;91:1042-5.
17. Melling J, Hambleton P, Shone CC Clostridium botulinum toxins: nature and preparation for clinical use. Eye (Lond) 1988;2 (Pt 1):16-23.
18. Jankovic J, Brin M F. Therapeutic uses of botulinum toxin. N Engl J Med 1991;324:1186-94.
19. Holds JB, Alderson K, Fogg S.G., et al Motor nerve sprouting in human orbicularis muscle after botulinum A injection. Invest Ophthalmol Vis Sci 1990;31:964-7.
20. dutton JJ. Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects. Surv Ophthalmol 1996;41:51-65.
21. Armstrong M.W., Mountain RE, Murray JA Treatment of facial synkinesis and facial asymmetry with botulinum toxin type A following facial nerve palsy. Clin Otolaryngol Allied Sci 1996;21:15-20.
22. Boroojerdi B, Ferbert A, Schwarz M., et al Botulinum toxin treatment of synkinesia and hyperlacrimation after facial palsy. J Neurol Neurosurg Psychiatr 1998;65:111-4.
23. Chua CN, Quhill F, Jones E., et al Treatment of aberrant facial nerve regeneration with botulinum toxin A. Orbit 2004;23:213-8.
24. Borodic G, Bartley M, Slattery W., et al Botulinum toxin for aberrant facial nerve regeneration: double-blind, placebo-controlled trial using subjective endpoints. Plast Reconstr Surg 2005;116:36-43.
25. Ito H, Ito H, Nakano S., et al Low-dose subcutaneous injection of botulinum toxin type A for facial synkinesis and hyperlacrimation. Acta Neurol Scand 2007;115:271-4.
26. Williams RS, Tse CK, dolly J.O., et al Radioiodination of botulinum neurotoxin type A with retention of biological activity and its binding to brain synaptosomes. Eur J Biochem 1983;131:437-45.
27. Toffola Ed, Furini F, Redaelli C., et al Evaluation and treatment of synkinesis with botulinum toxin following facial nerve palsy. Disabil Rehabil 2010;32:1414-8.